1. Dudarenko S.V., Kovalenko A.L., Prokopenko S.M., Belogurova E.V. Primenenie remaksola v terapii metabolicheskogo sindroma u patsientov s nealkogol’nym steatogepatitom i sakharnym diabetom 2 tipa [The use of remaxol in the treatment of metabolic syndrome in patients with nonalcoholic steatohepatitis and diabetes mellitus 2 type]. Eksperimental’naia i klinicheskaia gastroenterologiia [Experimental & clinical gastroenterology]. 2016;130(6):89–94. (In Russian).
2. Karkischenko N.N., Karkischenko V.N., Shustov E.B., Berzin I.A., Kapanadze G.D., Fokin Yu.V., et al. Biomeditsinskoe (doklinicheskoe) izuchenie lekarstvennykh sredstv, vliyayushchikh na fizicheskuyu rabotosposobnost’: Metod. rekom. [Biomedical (preclinical) studies of drugs modulating physical performance. Мethodological recommendations]. Moscow: Federal Medical and Biological Agency Publ., 2017. 134 p. (In Russian).
3. Moretti R., Caruso P., Gazzin S. Non-alcoholic fatty liver disease and neurological defects. Ann. Hepatol. 2019;18(4):563–570. DOI: 10.1016/j.aohep.2019.04.007.
4. Tsuchida T., Lee Y.A., Fujiwara N., et al. A simple dietand chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 2018;69(2):385–395. DOI: 10.1016/j.jhep.2018.03.011.